UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

 

Date of Report (Date of earliest event reported): October 30, 2019

 

LANNETT COMPANY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Commission File No. 001-31298

 

State of Delaware

 

23-0787699

(State of Incorporation)

 

(I.R.S. Employer I.D. No.)

 

9000 State Road

Philadelphia, PA 19136

(215) 333-9000

(Address of principal executive offices and telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

LCI

 

New York Stock Exchange

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 


 

ITEM 8.01 OTHER EVENTS

 

Beginning with Lannett Company, Inc’s. (“Lannett”, the “Company”, “our”) Form 10-Q for the period ended September 30, 2019, the Company will present updated and reclassified categories within our sales by medical indication table to better align with industry standards and our peers.  The Company believes this will provide for better comparability and clarity for the readers of our financial statements.  A reclassified sales by medical indication table of the Company’s quarterly fiscal year 2019 net sales is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d)     Exhibits

99.1   Fiscal year 2019 quarterly net sales by medical indication

 

2


 

EXHIBIT INDEX

 

Exhibit:

 

Description:

 

 

 

99.1

 

Fiscal year 2019 quarterly net sales by medical indication

 

3


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

LANNETT COMPANY, INC

 

 

 

By:

/s/ John Kozlowski

 

 

Vice President of Finance and Chief Financial Officer

 

Date:

October 31, 2019

 

 

4


Lannett (NYSE:LCI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Lannett Charts.
Lannett (NYSE:LCI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Lannett Charts.